Bethany Sensenig reports stock transactions at Supernus
By AlphaYouPublished Form 4
Sensenig Bethany
Reporting filer
Bethany Sensenig reports stock transactions, not an open-market purchase or sale, in Supernus, Inc.. Form 4 filed Nov 4, 2026 lists 5 entries.
- Disclosed
- Nov 4, 2026
Reported details
5 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units (derivative) | Sensenig Bethany | 2026-11-02 | J | Other (see filing) | 4603 | 0.00 | 4,603 | 2 days | Filed terms
|
| Director Stock Option (right to buy) (derivative) | Sensenig Bethany | 2026-11-02 | J | Other (see filing) | 37198 | 0.00 | 37,198 | 2 days | Filed terms
|
| Director Stock Option (right to buy) (derivative) | Sensenig Bethany | 2026-11-02 | J | Other (see filing) | 12708 | 0.00 | 12,708 | 2 days | Filed terms
|
| Director Stock Option (right to buy) (derivative) | Sensenig Bethany | 2026-11-02 | J | Other (see filing) | 11236 | 0.00 | 11,236 | 2 days | Filed terms
|
| Director Stock Option (right to buy) (derivative) | Sensenig Bethany | 2026-11-02 | J | Other (see filing) | 7665 | 0.00 | 7,665 | 2 days | Filed terms
|
Restricted Stock Units (derivative)
- Owner
- Sensenig Bethany
- Date
- 2026-11-02
- Code
- J
- Action
- Other (see filing)
- Quantity
- 4603
- Price
- 0.00
- Following holdings
- 4,603
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Restricted Stock Units
- conversion Or Exercise Price: 0.00
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 4603
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- exercise Date: 2027-02-18
- id: F2
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 4603
- shares Owned Following Transaction: 4603
- direct Or Indirect Ownership: D
Director Stock Option (right to buy) (derivative)
- Owner
- Sensenig Bethany
- Date
- 2026-11-02
- Code
- J
- Action
- Other (see filing)
- Quantity
- 37198
- Price
- 0.00
- Following holdings
- 37,198
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Director Stock Option (right to buy)
- conversion Or Exercise Price: 19.63
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 37198
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- exercise Date: 2024-08-17
- expiration Date: 2033-08-17
- underlying Security Title: Common Stock
- underlying Security Shares: 37198
- shares Owned Following Transaction: 37198
- direct Or Indirect Ownership: D
Director Stock Option (right to buy) (derivative)
- Owner
- Sensenig Bethany
- Date
- 2026-11-02
- Code
- J
- Action
- Other (see filing)
- Quantity
- 12708
- Price
- 0.00
- Following holdings
- 12,708
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Director Stock Option (right to buy)
- conversion Or Exercise Price: 18.15
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 12708
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- exercise Date: 2025-02-22
- expiration Date: 2034-02-22
- underlying Security Title: Common Stock
- underlying Security Shares: 12708
- shares Owned Following Transaction: 12708
- direct Or Indirect Ownership: D
Director Stock Option (right to buy) (derivative)
- Owner
- Sensenig Bethany
- Date
- 2026-11-02
- Code
- J
- Action
- Other (see filing)
- Quantity
- 11236
- Price
- 0.00
- Following holdings
- 11,236
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Director Stock Option (right to buy)
- conversion Or Exercise Price: 21.77
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 11236
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- exercise Date: 2026-02-19
- expiration Date: 2035-02-19
- underlying Security Title: Common Stock
- underlying Security Shares: 11236
- shares Owned Following Transaction: 11236
- direct Or Indirect Ownership: D
Director Stock Option (right to buy) (derivative)
- Owner
- Sensenig Bethany
- Date
- 2026-11-02
- Code
- J
- Action
- Other (see filing)
- Quantity
- 7665
- Price
- 0.00
- Following holdings
- 7,665
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Director Stock Option (right to buy)
- conversion Or Exercise Price: 32.60
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: J
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 7665
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- exercise Date: 2027-02-18
- expiration Date: 2036-02-18
- underlying Security Title: Common Stock
- underlying Security Shares: 7665
- shares Owned Following Transaction: 7665
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Sensenig Bethany: Director.
- F1: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.
- F2: These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.
Original sources
Prepared automatically from public filing data. Report a correction.